Treatment cost a major barrier in hypertension management

One of the major constraints for controlling hypertension is the limitation of resources for health care, reports the World Health Organization.

This is particularly true in low- and middle-income countries such as the Philippines, which contribute to 80 percent of the global cardiovascular burden.

The high cost of medicines is the most common reason why patients with hypertension cannot effectively manage their condition. When not managed effectively, high blood pressure can lead to serious complications or even death, an unfortunate result when there is not enough money available to sustain long-term treatment.

Effective and affordable brands of medicine can be an answer to the problem of treatment non-compliance. If the patient has the option to buy an affordable yet bioequivalent medicine, it is most likely that he would adhere to the treatment regimen recommended by his doctor.

Therapharma, a division of United Laboratories and a known advocate of pharmacoeconomics, will soon be launching a new brand of amlodipine.

Amlodipine is one of the most prescribed drugs for hypertension. It is also one of the most expensive drugs at P77 per tablet. Though a potent medicine, a few can only afford it.

With the introduction of a new and affordable brand in the market, more patients can enjoy the protection provided by amlodipine.

In keeping with the Therapharma tradition of providing patients with safe, effective and affordable medicines, the new amlodipine will be marketed at 50 percent less than the prevailing price of the originator brand.

This will pave the way for an improved treatment compliance among hypertensive patients which will eventually turn into better blood pressure management.

In addition to this, hypertensive patients will also prevent costly complications brought about by uncontrolled blood pressure.

The new amlodipine will provide a smart choice for hypertensive patients which will help prolong lives.